Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 January 2022Website:
http://www.vigilneuro.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:44:22 GMTDividend
Analysts recommendations
Institutional Ownership
VIGL Latest News
Vigil Neuroscience (NASDAQ: VIGL ) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ: SNY ). This investment has Sanofi purchasing 537,634 shares of Series A non-voting preferred shares at a price of $7.44 each.
LEUVEN, Belgium--(BUSINESS WIRE)-- #ALS--Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gemma Fri.
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management's participation at two upcoming investor conferences.
Vigil Neuroscience (VIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Tuesday, March 19th at 3:30 p.m. E.T.
Positive interim results reported from phase 2 IGNITE study using iluzanebart for ALSP treatment from 6 patients. Additional results from phase 2 IGNITE study usung iluzanebart for the treatment of patients with ALSP from both 20 mg and 40 mg doses expected Q3 of 2024. Data from IGNITE study and ILLUMINATE study are going to be discussed with the FDA so that the company can possibly obtain Accelerated Approval pathway of iluzanebart for ALSP.
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 1:30 p.m. ET.
Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial function. Their lead candidate, VGL101, is a monoclonal antibody agonist of TREM2, a microglial receptor protein involved in regulating microglial activation and phagocytosis. VGL101 has shown favorable safety and tolerability in phase 1 trials, with proof-of-target engagement and pharmacologic activity. Phase 2 data is expected in Q4.
What type of business is Vigil Neuroscience?
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
What sector is Vigil Neuroscience in?
Vigil Neuroscience is in the Healthcare sector
What industry is Vigil Neuroscience in?
Vigil Neuroscience is in the Biotechnology industry
What country is Vigil Neuroscience from?
Vigil Neuroscience is headquartered in United States
When did Vigil Neuroscience go public?
Vigil Neuroscience initial public offering (IPO) was on 07 January 2022
What is Vigil Neuroscience website?
https://www.vigilneuro.com
Is Vigil Neuroscience in the S&P 500?
No, Vigil Neuroscience is not included in the S&P 500 index
Is Vigil Neuroscience in the NASDAQ 100?
No, Vigil Neuroscience is not included in the NASDAQ 100 index
Is Vigil Neuroscience in the Dow Jones?
No, Vigil Neuroscience is not included in the Dow Jones index
When does Vigil Neuroscience report earnings?
The next expected earnings date for Vigil Neuroscience is 08 August 2024